Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.

BMC neurology - 9 Nov 2021

Zhou Kaijia, Jiang Tao, Liu Yanwei, Zhao Zheng, Huang Lijie, Li Guanzhang

Abstract excerpt

PURPOSE: Glioma is the most common primary intracranial tumor. Owing to the poor prognosis associated with high-grade gliomas, there is an urgent need to identify biomarkers related to prognosis and treatment sensitivity. Here, we analyze the expression of FXYD2 mRNA in gliomas, and explore its clinical prognostic value and significance in this disease. METHODS: Clinical features, FXYD2 mRNA expression levels,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Share to RNA, Messenger

Share to Sodium-Potassium-Exchanging ATPase

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 34753441
DOI: 10.1186/s12883-021-02476-2
PMCID: PMC8576926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.PMID 34753441Read ↗

FXYD2 mRNA Expression Represents a New Independent Factor That Affects Survival of Glioma Patients and Predicts Chemosensitivity of Patients to TemozolomideSemantic proximity Read ↗

Integrated Analysis Identifies MEOX2 as a Malignant Driver and Prognostic Biomarker in Brain GliomaSemantic proximity Read ↗

TMEM2 Combined with IDH and 1p19q in Refining Molecular Subtypes for Predicting Survival of Patients with Glioma.Semantic proximity Read ↗

Prognostic value and drug sensitivity of FBXL6 in gliomaSemantic proximity Read ↗

DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in gliomaSemantic proximity Read ↗

Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.Semantic proximity Read ↗

CPLX2 is a novel tumor suppressor and improves the prognosis in gliomaSemantic proximity Read ↗

ANXA2 is Correlated With the Molecular Features and Clinical Prognosis of Glioma, and Acts as a Potential Marker of ImmunosuppressionSemantic proximity Read ↗

FoxD2-AS1is a prognostic factor in glioma and promotes temozolomide resistance in a O6-methylguanine-DNA methyltransferase-dependent mannerSemantic proximity Read ↗

ZMYND8 as a novel diagnostic and prognostic biomarker in GliomaSemantic proximity Read ↗

ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppressionSemantic proximity Read ↗

TTF2 as a Potential Biomarker and Immunotherapy Target in Glioma Diagnosis and PrognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.